share_log

Kovo Announces Shares for Debt Transaction and Debt Restructuring

Kovo Announces Shares for Debt Transaction and Debt Restructuring

Kovo宣佈股票用於債務交易和債務重組
newsfile ·  05/22 20:32

Vancouver, British Columbia--(Newsfile Corp. - May 22, 2024) - Kovo Healthtech Corporation (TSXV: KOVO) ("Kovo" or the "Corporation") is pleased to announce that it has entered into a shares for debt agreement (the "Shares for Debt Agreement") with the Corporation's largest secured creditor, Avonlea Ventures #2 Inc. ("AVI"), a company controlled by Mr. Michael Steele, a director of the Corporation. The transaction forms part of a larger restructuring of the Corporation's debt. Pursuant to the Shares for Debt Agreement, Kovo's outstanding indebtedness to AVI, will be reduced by an aggregate of CDN$2,257,229.56 through the conversion of such outstanding indebtedness into common shares in the capital of the Corporation ("Common Shares"), at a deemed issue price per Common Share equal to $0.035 in respect of 57,543,906 Common Shares and $0.05 in respect of 4,863,861 Common Shares (the "Debt Conversion Transaction").

不列顛哥倫比亞省溫哥華--(Newsfile Corp.,2024 年 5 月 22 日)-Kovo Healthtech Corporation(TSXV:KOVO)(”科沃“或者”公司“)很高興地宣佈,它已簽訂股份換債協議(”股份換債協議“) 與該公司最大的有擔保債權人Avonlea Ventures #2 Inc. (”AVI“),一家由公司董事邁克爾·斯蒂爾先生控制的公司。該交易是公司更大規模的債務重組的一部分。根據股份換債協議,通過將此類未償債務轉換爲公司資本中的普通股,Kovo對AVI的未償債務總額將減少2,257,229.56加元(”普通股“),每股普通股的認定發行價格等於57,543,906股普通股的0.035美元,4,863,861股普通股的認定發行價格爲0.05美元(”債務轉換交易“)。

Following the Debt Conversion Transaction, and AVI's agreement to reduce a portion of fees owing to it, Kovo will continue to owe approximately USD$4,340,039 (the "Remaining Indebtedness") to AVI under the senior loan and security agreement dated as of April 20, 2023 (collectively, the "Loan Agreement"), as amended pursuant to a forbearance agreement dated February 27, 2024 (the "Forbearance Agreement") and pursuant to a letter agreement April 23, 2024. In connection with the Debt Conversion Transaction, AVI and the Corporation have agreed to amend and restate to the Loan Agreement to extend the maturity date of the Remaining Indebtedness to April 30, 2025 and provide AVI with the right to convert the Remaining Indebtedness into Common Shares (the "Additional Conversion Right") at a fixed price of CDN$0.05 per share and at the prevailing market price in respect of future interest in accordance with TSX Venture Exchange policies (the "Loan Agreement Amendments", with the Debt Conversion Transaction and the Loan Agreement Amendments collectively, the "Transaction"). Upon final TSX Venture Exchange (the "TSXV") acceptance, the Forbearance Agreement will terminate, and the Corporation will no longer be subject to the default interest rate provided for in the Loan Agreement.

繼債務轉換交易以及AVI同意減少應付的部分費用之後,Kovo將繼續欠約4,340,039美元(”剩餘債務“) 根據截至2023年4月20日的優先貸款和擔保協議(統稱爲”貸款協議“),根據2024年2月27日的寬容協議進行了修訂(”寬容協議“)並根據2024年4月23日的一份書面協議。關於債務轉換交易,AVI和公司已同意修改和重申《貸款協議》,將剩餘債務的到期日延長至2025年4月30日,並賦予AVI將剩餘債務轉換爲普通股的權利(”額外轉換權“)根據多倫多證券交易所風險交易所的政策,以每股0.05加元的固定價格和未來利息的現行市場價格計算(”貸款協議修正案“,加上債務轉換交易和貸款協議修正案的總和,”交易“)。在多倫多證券交易所風險投資交易所最終確定後(”TSXV“)接受,寬容協議將終止,公司將不再受貸款協議中規定的違約利率的約束。

In aggregate, a total of 62,407,767 Common Shares (the "Settlement Shares") will be issued by the Corporation pursuant to the Debt Conversion Transaction all of which will be owned or controlled, directly or indirectly, by AVI. Following the issuance of the Settlement Shares, the Corporation will have 119,951,673 Common Shares issued and outstanding and AVI will own or control, directly or indirectly, 80,007,767 Common Shares, 8,800,000 warrants to acquire Common Shares (having an expiry date of April 20, 2025 and an exercise price of $0.40 per share) and the right to acquire additional Common Shares pursuant to the Additional Conversion Right (which, on the date hereof, would represent a right to acquire an additional 118,179,262 Common Shares at CDN$0.05 per share, based on the amount of the Remaining Indebtedness and the CAD/US exchange ratio in effect as of May 20, 2024), representing approximately 66.7% of the total issued and outstanding Common Shares on a non-diluted basis and 83.8% of the outstanding shares on a partially diluted basis (assuming the exercise of such warrants and the Additional Conversion Right). AVI was previously approved by the shareholders of Kovo as a new "Control Person" in connection with the private placement announced in the Corporation's press release dated April 21, 2023.

總共有62,407,767股普通股(”結算股份“)將由公司根據債務轉換交易發行,所有這些交易都將由AVI直接或間接擁有或控制。發行結算股後,公司將發行和流通119,951,673股普通股,AVI將直接或間接擁有或控制80,007,767股普通股、8,800,000份普通股收購權證(到期日爲2025年4月20日,行使價爲每股0.40美元)以及根據額外轉換權(在本文發佈之日)收購額外普通股的權利,將代表根據金額以每股0.05加元的價格額外收購118,179,262股普通股的權利剩餘負債和截至2024年5月20日生效的加元/美國匯率比率),約佔未攤薄後已發行和流通普通股總額的66.7%,部分攤薄後佔已發行股票的83.8%(假設行使了此類認股權證和額外轉換權)。AVI此前曾被Kovo的股東批准爲新的 “控制人”,這與該公司在2023年4月21日的新聞稿中宣佈的私募有關。

AVI is considered to be a "related party" of Kovo within the meaning of Multilateral Instrument 61-101 – Protections of Minority Security Holders in Special Transactions ("MI 61-101"). The Transaction with AVI constitutes a "related party transaction" within the meaning of MI 61-101. MI 61-101 regulates transactions that raise the potential for conflicts of interest, including transactions involving parties who are "related parties" to the reporting issuer, as that term is used in MI 61-101. Among other things, MI 61-101 requires, in certain instances, that unless an exemption is available or discretionary relief is granted by applicable securities regulatory authorities, a reporting issuer proposing to carry out a related party transaction is required to: (i) engage an independent valuator to prepare a valuation of the affected securities (and any non-cash consideration being offered therefore) and provide to the holders of the affected securities a summary of such valuation (the "Formal Valuation Requirement"); and (ii) obtain the approval of a majority of the "minority" shareholders (as that term is used in MI 61-101) (the "Minority Approval Requirement").

根據第61-101號多邊文書的定義,AVI被視爲Kovo的 “關聯方” — 在特殊交易中保護少數證券持有人 (”MI 61-101“)。與AVI的交易構成了MI 61-101所指的 “關聯方交易”。密歇根州61-101監管可能引發利益衝突的交易,包括涉及申報發行人 “關聯方” 的交易,該術語在密歇根州61-101中使用。除其他外,密歇根州61-101要求,在某些情況下,除非適用的證券監管機構給予豁免或全權救濟,否則提議進行關聯方交易的申報發行人必須:(i)聘請獨立估值師對受影響證券(以及因此提供的任何非現金對價)進行估值,並向受影響證券的持有人提供此類估值的摘要(”正式估值要求“);以及(ii)獲得大多數 “少數” 股東的批准(該術語在密歇根州61-101中使用)(”少數族裔批准要求“)。

Subject to the TSXV's potential application of its discretion in section 3.1 of TSXV Policy 5.9, Kovo intends to rely on the exemption from the Formal Valuation Requirement of the instrument for any "related party transaction" by virtue of the exemption contained in section 5.5(b) (Issuer Not Listed on Specified Markets), as no securities of Kovo are listed or quoted on the Toronto Stock Exchange, Aequitas NEO Exchange Inc., the New York Stock Exchange, the American Stock Exchange, the NASDAQ Stock Market, or a stock exchange outside of Canada and the United States.

根據多倫多證券交易所可能行使多倫多證券交易所政策5.9第3.1節中的自由裁量權,Kovo打算根據第5.5(b)節(發行人未在特定市場上市)中的豁免,依賴該工具正式估值要求的豁免來進行任何 “關聯方交易”,因爲Kovo的證券沒有在多倫多證券交易所、Aequitas NEO Exchange Inc.、紐約證券交易所上市或上市,美國證券交易所、納斯達克股票市場或加拿大和美國以外的證券交易所各州。

Additionally, Kovo is exempt from the Formal Valuation Requirement and Minority Approval Requirement as it is relying on the exemption contained in sections 5.5(g) and 5.7(1)(e) (Financial Hardship) (the "Financial Hardship Exemption") of MI 61-101 on the basis that: (i) Kovo was (and continues to be) in serious financial difficulty; (ii) the Transaction was designed to improve the financial position of Kovo; (iii) paragraph 5.5(f) (Bankruptcy, Insolvency, Court Order) of MI 61-101 was not applicable; and (iv) Kovo's board of directors, acting in good faith, and at least two-thirds of Kovo's independent directors, acting in good faith, determined that: (A) Kovo was (and continues to be) in serious financial difficulty and the Transaction was designed to improve the financial position of Kovo, and (B) the terms of the Transaction were reasonable in the circumstances.

此外,Kovo不受正式估值要求和少數族裔批准要求的約束,因爲它依賴於第5.5(g)和5.7(1)(e)節(財務困難)中包含的豁免(”財務困難豁免“) 密歇根州61-101的依據是:(i)Kovo過去(並將繼續)陷入嚴重的財務困境;(ii)該交易旨在改善Kovo的財務狀況;(iii)密歇根州61-101的第5.5(f)段(破產、破產、法院命令)不適用;(iv)本着誠意行事的Kovo董事會,以及Kovo的至少三分之二的股份獨立董事本着誠意行事,認定:(A)Kovo過去(並將繼續)陷入嚴重的財務困境,該交易旨在改善Kovo的財務狀況,以及 (B) 交易條款在當時情況下是合理的。

The Shares issued pursuant to the Shares for Debt Agreement will be subject to a four month plus one day hold period pursuant to the policies of the TSXV.

根據多倫多證券交易所的政策,根據股份換債協議發行的股票將有四個月加一天的持有期。

It is Kovo's expectation that if the Transaction is not completed, AVI will enforce its security to realize upon payment of the indebtedness as a consequence of Kovo's financial condition. In the event this occurs, it is anticipated that Kovo shareholders would not realize any return on their investment.

由於Kovo的財務狀況,Kovo預計,如果交易未完成,AVI將強制執行其擔保,以便在償還債務時兌現。如果發生這種情況,預計Kovo股東將無法實現任何投資回報。

The Corporation anticipates that the closing of the Transaction will occur as soon as possible. As a result, closing of the Debt Conversion Transaction and effectiveness of the Loan Amendments may occur less than 21 days after the date of this press release. The issuance of the Settlement Shares and the effectiveness Loan Agreement Amendments remain subject to acceptance and final approval of the TSXV.

該公司預計,該交易將盡快完成。因此,債務轉換交易的完成和貸款修正案的生效可能在本新聞稿發佈之日後不到21天內發生。結算股份的發行和貸款協議修正案的有效性仍有待多倫多證券交易所的接受和最終批准。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險投資交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

About Kovo HealthTech Corporation

關於 Kovo 健康科技公司

Kovo HealthTech Corporation is a growing healthcare technology company that specializes in Billing-as-a-Service offering SaaS-style recurring revenue contracts and software for more than 2250 US healthcare providers. Kovo helps healthcare providers digitally track and manage complex patient care registration, services, billing and payments in a seamless way. Currently, through its clients, Kovo processes over $250 million CAD ($200M USD) in annual billing transactions for more than 3.5 million patients. By offering effective billing practices, Kovo helps healthcare practitioners get paid so they can focus on offering quality care. To learn more about Kovo and to keep up-to-date on Kovo news, visit .

Kovo HealthTech Corporation是一家成長中的醫療保健技術公司,專門從事計費即服務,爲2250多家美國醫療保健提供商提供SaaS式的經常性收入合同和軟件。Kovo 幫助醫療保健提供商以數字方式無縫跟蹤和管理複雜的患者護理登記、服務、賬單和付款。目前,Kovo通過其客戶爲超過350萬名患者處理超過2.5億加元(合2億美元)的年度賬單交易。通過提供有效的計費方式,Kovo幫助醫療保健從業人員獲得報酬,使他們能夠專注於提供優質的醫療服務。要了解有關 Kovo 的更多信息並及時了解 Kovo 的最新消息,請訪問

For more information:
Greg Noble, CEO
investors@kovo.co
1-866-558-6777

欲了解更多信息:
首席執行官格雷格諾布爾
investors@kovo.co
1-866-558-6777

Forward-Looking Information

前瞻性信息

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the Corporation's settlement of certain debt obligations owed to entities controlled by a current directors of the Corporation, the future financial condition of the Corporation and its prospects, including any proposed debt restructuring transaction, including the Debt Conversion Transaction and the Loan Agreement Amendments. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Corporation. Although management of the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

本新聞稿包含適用證券法所指的前瞻性陳述和前瞻性信息。這些陳述與未來事件或未來表現有關。除歷史事實陳述以外的所有陳述可能是前瞻性陳述或信息。更具體地說,不限於,本新聞稿包含前瞻性聲明和信息,涉及公司清償欠公司現任董事控制的實體的某些債務、公司的未來財務狀況及其前景,包括任何擬議的債務重組交易,包括債務轉換交易和貸款協議修正案。前瞻性陳述和信息基於公司管理層做出的某些關鍵預期和假設。儘管公司管理層認爲此類前瞻性陳述和信息所依據的預期和假設是合理的,但不應過分依賴前瞻性陳述和信息,因爲無法保證這些陳述和信息會被證明是正確的。

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Corporation relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Corporation's ability to continue operations without adequate capital, the Corporation's ability to raise further capital, the Corporation's ability to meet the terms of its current debt obligations and to repay its indebtedness with or without the Debt Conversion Transaction and the Loan Agreement Amendments, the likelihood of the Corporation satisfying its ongoing obligations under the proposed Debt Conversion Transaction and Loan Agreement Amendments, the Corporation's ability to efficiently and successfully develop new opportunities, failure to identify future transactional counter-parties, and the likelihood of any debt restructuring transaction being consummated, and the Corporation not defaulting in the future. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

提供前瞻性陳述和信息的目的是提供有關公司當前對未來的預期和管理計劃的信息。提醒讀者,依賴此類陳述和信息可能不適合用於其他目的,例如做出投資決策。由於前瞻性陳述和信息涉及未來的事件和狀況,因此就其本質而言,它們涉及固有的風險和不確定性。由於許多因素和風險,實際結果可能與目前的預期有重大差異。其中包括但不限於公司在沒有足夠資本的情況下繼續運營的能力、公司籌集更多資金的能力、公司履行其當前債務義務條款和償還債務的能力,無論是否進行債務轉換交易和貸款協議修正案,公司履行其在擬議的債務轉換交易和貸款協議修正案下的持續義務的可能性,公司高效成功發展的能力新的機會,未能確定未來的交易對手,任何債務重組交易完成的可能性,以及公司將來不會違約。因此,讀者不應過分依賴本新聞稿中包含的前瞻性陳述和信息。請讀者注意,上述因素清單並不詳盡。本新聞稿中包含的前瞻性陳述和信息自發布之日起作出,除非適用的證券法有要求,否則不承諾公開更新或修改任何前瞻性陳述或信息,無論是由於新信息、未來事件還是其他原因。本警告聲明明確限制了本新聞稿中包含的前瞻性陳述或信息。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論